Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study - PubMed (original) (raw)
Randomized Controlled Trial
. 2008 Feb;158(2):179-87.
doi: 10.1530/EJE-07-0721.
Affiliations
- PMID: 18230824
- DOI: 10.1530/EJE-07-0721
Randomized Controlled Trial
Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study
Erik L Madsen et al. Eur J Endocrinol. 2008 Feb.
Abstract
Objective: To investigate the effects of: I) short- (8 weeks), II) long-term (3 years) weight loss, and III) the degree of weight loss on circulating levels of adiponectin, high sensitive-C reactive protein (hs-CRP), and fibrinogen in obese subjects. Moreover, to evaluate the effect of the lipase inhibitor, orlistat, on these parameters.
Design: Weight loss induced in 93 obese subjects (mean weight: 108.9+/-15.8 kg) through 8-week very-low-energy diet (VLED, 800 kcal/day) followed by randomization to orlistat or placebo together with lifestyle intervention for further 3 years. Adiponectin and hs-CRP were measured at baseline, after 8 weeks of VLED and 6, 12, and 36 months after the VLED by flowmetric xMAP technology (Luminex Multi-Analyte Profiling System, Luminex Corp., Austin, TX, USA). Fibrinogen was measured in a coagulation assay.
Results: Weight loss after VLED treatment was 14.3+/-4.5 kg and after 3 years 7.7+/-8.7 kg. Orlistat-treated subjects regained 3.9 kg less than placebo-treated from the end of the VLED to 3 years (P=0.01). No differences were detected between the two groups regarding changes in adiponectin, hs-CRP, or fibrinogen. Accordingly, the groups were combined for further analyses. Serum adiponectin increased by 22% (P<0.05) after the VLED but returned to baseline after 3 years. Both short- and long-term weight losses needed to be in excess of 10% (approximately 12 kg) in order to increase adiponectin levels significantly. Weight loss was associated with a significant decrease in hs-CRP. Fibrinogen decreased by 12% (P<0.05) after 3 years.
Conclusions: In obese subjects, weight loss was associated with an increase in serum adiponectin and a decrease in hs-CRP and plasma fibrinogen. Long-term weight loss (3 years) must exceed 10% to induce a combined significant improvement in these inflammatory markers.
Similar articles
- Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects.
Madsen EL, Bruun JM, Skogstrand K, Hougaard DM, Christiansen T, Richelsen B. Madsen EL, et al. Metabolism. 2009 Jul;58(7):946-53. doi: 10.1016/j.metabol.2009.02.031. Metabolism. 2009. PMID: 19409578 Clinical Trial. - Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
Richelsen B, Tonstad S, Rössner S, Toubro S, Niskanen L, Madsbad S, Mustajoki P, Rissanen A. Richelsen B, et al. Diabetes Care. 2007 Jan;30(1):27-32. doi: 10.2337/dc06-0210. Diabetes Care. 2007. PMID: 17192328 Clinical Trial. - The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
Muls E, Kolanowski J, Scheen A, Van Gaal L; ObelHyx Study Group. Muls E, et al. Int J Obes Relat Metab Disord. 2001 Nov;25(11):1713-21. doi: 10.1038/sj.ijo.0801814. Int J Obes Relat Metab Disord. 2001. PMID: 11753595 Clinical Trial. - First clinical studies with orlistat: a short review.
Drent ML, van der Veen EA. Drent ML, et al. Obes Res. 1995 Nov;3 Suppl 4:623S-625S. doi: 10.1002/j.1550-8528.1995.tb00236.x. Obes Res. 1995. PMID: 8697067 Review. - New aspects in the management of obesity: operation and the impact of lipase inhibitors.
Uusitupa M. Uusitupa M. Curr Opin Lipidol. 1999 Feb;10(1):3-7. doi: 10.1097/00041433-199902000-00002. Curr Opin Lipidol. 1999. PMID: 10095983 Review.
Cited by
- Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome.
Fuentes E, Fuentes F, Vilahur G, Badimon L, Palomo I. Fuentes E, et al. Mediators Inflamm. 2013;2013:136584. doi: 10.1155/2013/136584. Epub 2013 Jun 13. Mediators Inflamm. 2013. PMID: 23843680 Free PMC article. Review. - Subclinical Vascular Damage: Current Insights and Future Potential.
Mattioli AV, Coppi F, Manenti A, Farinetti A. Mattioli AV, et al. Vasc Health Risk Manag. 2021 Nov 22;17:729-738. doi: 10.2147/VHRM.S242636. eCollection 2021. Vasc Health Risk Manag. 2021. PMID: 34866906 Free PMC article. Review. - Effects of Aerobic Exercise on Serum Adiponectin Concentrations in Children and Adolescents with Obesity: A Systematic Review and Meta-Analysis.
Zhang Y, Wu Y, Fei X, Li Y, Li Y, Yan X. Zhang Y, et al. Life (Basel). 2023 Aug 18;13(8):1772. doi: 10.3390/life13081772. Life (Basel). 2023. PMID: 37629629 Free PMC article. Review. - Resistance Training Prevents Muscle Loss Induced by Caloric Restriction in Obese Elderly Individuals: A Systematic Review and Meta-Analysis.
Sardeli AV, Komatsu TR, Mori MA, Gáspari AF, Chacon-Mikahil MPT. Sardeli AV, et al. Nutrients. 2018 Mar 29;10(4):423. doi: 10.3390/nu10040423. Nutrients. 2018. PMID: 29596307 Free PMC article. Review. - Decreased adiponectin level is associated with aggressive phenotype of tongue squamous cell carcinoma.
Guo XH, Wang JY, Gao Y, Gao M, Yu GY, Xiang RL, Li L, Yang NY, Cong X, Xu XY, Li SL, Peng X, Wu LL. Guo XH, et al. Cancer Sci. 2013 Feb;104(2):206-13. doi: 10.1111/cas.12077. Epub 2013 Jan 20. Cancer Sci. 2013. PMID: 23181352 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous